Sustained-release injection composition for combined treatment of risperidone and CYP2D6 enzyme inhibitor
A sustained-release injectable composition with risperidone and PLGA copolymer addresses medication adherence and drug-drug interactions by maintaining therapeutic levels for 28-31 days, reducing adverse events and effectively treating schizophrenia with CYP2D6 inhibitors.
Patent Information
- Application Number
- CN202380034464.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-18
- Filing Date
- 2023-05-18
- Publication Date
- 2024-12-03
AI Technical Summary
Existing long-acting injectable (LAI) reservoir compositions for risperidone do not effectively address the challenges of medication adherence issues and drug-drug interactions, particularly with CYP2D6 enzyme inhibitors like SSRIs, leading to fluctuating blood concentrations and adverse events.
A sustained-release injectable composition containing risperidone and PLGA copolymer, administered every 28 days, which maintains therapeutic blood levels without the need for oral supplementation or loading doses, even when co-administered with CYP2D6 inhibitors.
The composition provides stable therapeutic levels of risperidone for 28-31 days, reduces adverse events, and effectively treats acute exacerbations of schizophrenia without the need for dose adjustments, improving medication adherence and clinical efficacy.
Smart Images

Figure BDA0005087199280000061 
Figure BDA0005087199280000181 
Figure BDA0005087199280000182
Abstract
Description
Technical Field
[0001] The present invention relates to a composition for a method of treating a risperidone or paliperidone-sensitive disease, disorder or condition in a subject receiving one or more other therapeutic agents as CYP2D6 (cytochrome P450 2D6) enzyme inhibitor in combination with risperidone. In particular, the method administers risperidone and one or more other therapeutic agents in the same dosage form or in different dosage forms. Risperidone is contained in a long-acting injectable (LAI) reservoir composition (sustained release injectable suspension), which contains risperidone for treating risperidone or paliperidone-sensitive diseases, disorders or conditions. CYP2D6 enzyme inhibitors can be used to treat one or more diseases.
[0002] The method provides for intramuscular injection of a sustained-release injection composition approximately once every 28 days (or approximately monthly), without the need for prior administration of a loading dose of risperidone, and without the need for simultaneous administration of the sustained-release injection composition and a risperidone oral supplement. From the first day of administration (within 8-24 hours after administration), the composition can provide a therapeutically effective blood concentration of risperidone for at least about 28-31 days or longer. The performance of the composition is improved compared to other LAI reservoir compositions. For patients receiving one or more other therapeutic agents, the dose of risperidone in the sustained-release injection composition is preselected to reduce the effect of the one or more other therapeutic agents on the blood concentration of risperidone and / or its metabolites (9-hydroxy-risperidone; paliperidone). Background Art
[0003] Patients with schizophrenia or bipolar disorder are often treated with risperidone. However, these patients also often suffer from depression, which can be treated with antidepressants called selective serotonin reuptake inhibitors (SSRIs).
[0004] Paroxetine hydrochloride (PAXIL) and fluoxetine (PROZAC) are SSRI antidepressants used to treat depression, panic attacks, obsessive-compulsive disorder (OCD), and severe premenstrual syndrome (premenstrual dysphoric disorder). PAXIL is also used to treat anxiety disorders (social anxiety and / or general anxiety) and post-traumatic stress disorder. In addition, PROZAC is used to treat bulimia nervosa, major depressive disorder, panic disorder, depressive disorder associated with bipolar I disorder (in combination with olanzapine (ZYPREXA)), and in combination with olanzapine (ZYPREXA) to treat refractory depression (depression that has not improved after at least two other treatments).
[0005] Paroxetine and fluoxetine are potent CYP2D6 inhibitors. Risperidone is metabolized primarily to 9-hydroxy-risperidone (paliperidone) by CYP2D6, so administering risperidone and SSRI to subjects may cause adverse changes in risperidone blood concentrations. Neither the package inserts of PROZAC nor PAXIL provide guidance on how to change the mode of administration for subjects receiving a sustained-release injection composition containing risperidone, particularly the sustained-release injection composition of the present invention as described herein, when receiving PROZAC or PAXIL treatment. The overall blood concentration curves produced by daily oral administration of risperidone are different from those produced by monthly injections of risperidone sustained-release injection compositions. Therefore, the recommended daily oral administration of risperidone cannot be used as a guide for determining the mode of administration in monthly intramuscular injections of risperidone sustained-release injection compositions.
[0006] Schizophrenia can present with varying degrees of severity. Many psychotic patients with this disorder can achieve symptom stabilization with oral antipsychotic medications; however, it is estimated that up to 75% of patients have difficulty adhering to their daily oral treatment regimen, i.e., have medication adherence problems. Medication adherence problems often lead to worsening symptoms, poor efficacy, frequent relapses and re-hospitalizations, and a failure to benefit from rehabilitation and psychosocial treatments.
[0007] Risperidone and its major active metabolite 9-hydroxy-risperidone (paliperidone) are suitable for the treatment of psychotic disorders such as schizophrenia, schizoaffective disorder, bipolar disorder and bipolar mania. Risperidone can be administered orally in the form of commercially available tablets, solutions or orally disintegrating tablets.
[0008] Many papers discuss the appropriate use of oral risperidone and risperidone with LAI to treat different degrees of schizophrenia. Citrome (Clinical Schizo. Related Psych., (2018), 130-141), Bai et al. (Pharmacopsych. (2006), 39, 135-141) and Andorn et al. (J. Clin. Psychopharm., (2019), 39 (5), 428-433). Relapsed schizophrenia patients require urgent treatment because of the severity of symptoms. If not treated immediately, it will have an impact on the future.
[0009] Risperidone is indicated for the treatment of psychotic disorders such as schizophrenia and bipolar disorder. Risperidone is available in both immediate-release (immediate-release) and extended-release injection forms.
[0010] The following LAI reservoir compositions are known: US 8,221,778 to Siegel et al. (corresponding to WO 2005 / 070332); US 5,688,801, US 6,803,055, US 5,770,231, US 7,118,763 and US 4,389,330 to Dunn; US 4,530,840 and US 6,673,767 to Brodebeck; US 6,143,314 to Chandrashekar; WO 2004 / 081196, WO 2001 / 035929 and WO 2008 / 153611A2 to QLT USA; WO 2000 / 024374, WO 2001 / 035929 and WO 2008 / 153611A2 to Laboratorios Farmaceuticos ROVI, SA; 2002 / 038185, WO 2008 / 100576 and WO 2011 / 151355 A1; WO 2011 / 42453 and US10085936 granted to Gutierro Aduriz; US10463607 granted to Gutierro Aduriz; US10182982 granted to Gutierro Aduriz; US2020 / 0085728 A1 granted to Gutierro Aduriz; EP 2394664 A1 granted to Laboratorios Farmaceuticos ROVI, S.A.; WO 2011 / 151355 A1 granted to Laboratorios Farmaceuticos ROVI, S.A.; US10058504 granted to Gutierro Aduriz; US10881605 granted to Gutierro Aduriz; Patent US10195138 granted to Aduriz; Patent US2021 / 0077380 A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent EP 2394663A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent WO 2011 / 151356 A2 granted to Laboratorios Farmaceuticos ROVI, SA; Patent US10350159 granted to Gutierro Aduriz; Patent US2021 / 0077380 A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent EP 2394663A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent WO 2011 / 151356 A2 granted to Laboratorios Farmaceuticos ROVI, SAPatent US 2019 / 0328654A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent EP 2529757 A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent WO 2013 / 178811 A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent US10335366 granted to Gutierro Aduriz; Patent US2019 / 0254960 A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent US11007139 granted to Gutierro Aduriz; Patent EP 2529756A2 granted to Laboratorios Farmaceuticos ROVI, SA; Patent WO 2013 / 178812A1 granted to Laboratorios Farmaceuticos ROVI, SA; Patent US2008 / 0287464 granted to Wright A1; US2009 / 0264491 A1 to McKay; US2004 / 0010224 A1 to Bodmeier; US2007 / 0077304 A1 to Luk; US 2010 / 0015195 A1 to Jain; US2010 / 0266655 A1 to Dadey; WO 95 / 29664 to Alkermes; WO 2004 / 011054 A2 to Alza; WO 2007 / 041410 A2 to Luk; WO 2008 / 059058 A1 to Bourges; and WO 2010 / 018159 A1 to Schoenhammer.
[0011] Two such LAI drug products containing risperidone have been approved by the U.S. Food and Drug Administration.
[0012] RISPERDAL (NDA N021346; dosage concentrations: 12.5 mg / vial, 25 mg / vial, 37.5 mg / vial and 50 mg / vial; US 6596316, US 6379703, US 6194006, WO 2000 / 40221) is a PLGA microparticle formulation containing risperidone for intramuscular injection, designed to deliver therapeutic levels of risperidone by administration once every two weeks. However, due to the inherent lag phase of most microparticle-based drugs, patients need to take daily oral doses of risperidone as a supplement in the first few weeks after the first dose. After about three weeks of daily oral administration of risperidone, the microspheres in the systemic circulation can release enough risperidone, and the patient can stop daily oral supplementation. However, there may be a risk of patients not complying with the treatment plan during oral supplementation. In addition, the presence of two doses in the body at the same time may bring potential risks of adverse events, such as irregular drug effects and drug toxicity.
[0013] (NDA N210655; dosage strengths: 90 mg and 120 mg per dose; US 9180197, US9186413, US 9597402, US10010612, US10058554, US10376590, US10406160) is a microparticle dosage form containing risperidone, intended for subcutaneous injection into adipose tissue. Nasser et al. (“Efficacy, safety and tolerance of RBP-7000once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter Phase 3 study” in J. Clin. Psycopharm. (2016), 36(2), 130-140) evaluated the use of RBP-7000 LAI (dose concentrations: 90 mg and 120 mg) for the treatment of acute schizophrenia.
[0014] Another LAI containing risperidone is still under clinical evaluation for the treatment of schizophrenia: Correll et al. (NPJ Schizophrenia (Nov. 25, 2020), 6:37), Edison Investment Research Limited (“Doria Phase III Trial hits primary endpoint,” Laboratorios Farmaceuticos ROVI, SA, Mar. 19, 2019, www.edisongroup.com / publication / doria-phase-iii-trial-hits-primary-endpoint / 23705 / ), NCT02086786, NCT03160521, NCT01788774, NCT01320410, NCT03870880, NCT03160521, NCT01788774; and Anta et al. (“Newer formulations of risperidone: remarks about risperidone ISM”, CNSDrugs, September 5, 2020). The ingredients of the drug product are not disclosed in these publications.
[0015] LAI depot compositions containing risperidone may interact differently with other drugs because such depot compositions vary in the mode of administration, the dose of risperidone administered, the formulation of the depot composition, and / or the pharmacokinetics provided by the depot composition. For example, the specificity of drug-drug interactions of PERSERIS is different from the specificity of drug-drug interactions of RISPERDAL CONSTA, and is also different from the specificity of drug-drug interactions of the extended-release injection composition used below according to the present invention.
[0016] Patent US6,331,311 granted to Brodbeck also discloses a sustained-release injection composition comprising a biocompatible polymer such as PLGA, a solvent such as N-methyl-2-pyrrolidone, and a beneficial agent such as a drug, and an emulsifier such as a polyol. However, when the beneficial agent is risperidone, the performance of the disclosed composition is not satisfactory because the use of a biphasic composition containing an emulsifier accelerates the hydration of the implant, increases the effective release surface area, and thus changes the control of the initial immediate release, resulting in a rapid decrease in the amount of drug released from the first few days to the following days. For example, a control composition was prepared according to patent US311. One of the containers used to prepare the composition contained risperidone (150 mg), PLGA (300 mg, inherent viscosity of 0.32 dl / g, irradiated with 25 kGy beta rays) and NMP (700 mg). Another container contained a polyvinyl alcohol aqueous solution (1 mL, 2% w / v). The contents of the two containers were mixed and the mixture was transferred to a syringe and injected into the buttocks muscle of New Zealand white rabbits (n=3) (dose equivalent to 2.5 mg risperidone). More than 70% of the total AUC of the active molecule was released within 5 days after injection. This formulation was unable to provide therapeutic levels of risperidone plasma concentrations for at least four weeks.
[0017] Patent US 4,938,763 granted to Dunn et al. discloses a method for injectable in situ forming implants. A biodegradable polymer or copolymer dissolved in a water-miscible solvent together with a bioactive agent is dissolved or dispersed in a polymer solution. Once the polymer solution contacts body fluids, the solvent diffuses and the polymer solidifies, thereby trapping the drug in the polymer matrix. Although Dunn et al. disclose the use of water-miscible solvents to obtain in situ forming polymer implants, they disclose a variety of polymers and solvents, even different component ratios, which cannot produce good implants with appropriate release characteristics, especially when the implant contains risperidone as an active ingredient. For example, a control composition was prepared according to patent US763. Risperidone (50 mg) and PLGA (784 mg, a ratio of lactic acid monomer to glycolic acid monomer of 75:25, and an intrinsic viscosity of 0.20 dl / g) were contained in one of the containers used to prepare the composition. NMP (1666 mg) was contained in another container. The contents of the two containers were mixed. The mixture was then transferred to a syringe and a portion (1250 mg, equivalent to 25 mg risperidone) was injected into an aqueous liquid to determine its in vitro release profile. More than 50% of the risperidone was released within the first 2 days. This formulation was unable to provide therapeutic levels of risperidone in the blood for at least four weeks.
[0018] Subjects receiving CYP2D6 enzyme inhibitors and oral risperidone should reduce the dose of oral risperidone because the inhibitor affects risperidone plasma concentrations. For example, the package insert for paroxetine hydrochloride (PAXIL) states that the initial and maintenance doses vary depending on the disease being treated. It also states: "Concomitant use of paroxetine and risperidone (a CYP2D6 substrate) has also been evaluated. In one study, patients who were stabilized on risperidone took paroxetine 20 mg daily (4 to 8 mg / day), and the mean plasma concentration of risperidone increased by approximately 4-fold, the concentration of 9-hydroxy-risperidone decreased by approximately 10%, and the concentration of the active molecule (the sum of risperidone and 9-hydroxy-risperidone) increased by approximately 1.4-fold. Therefore, the daily dose of oral risperidone should be adjusted (reduced, not maintained) based on the CYP2D6 dose administered."
[0019] When the sustained-release injection composition of the present invention is administered to a subject who is also receiving a CYP2D6 inhibitor such as an SSRI antidepressant (e.g., paroxetine or fluoxetine), the art in the field of LAI reservoir compositions does not describe specific dosage combinations. In view of the increasing popularity of sustained-release injection compositions containing risperidone, it would be a major advance in the art to provide a method for treating a patient with a sustained-release injection composition containing risperidone and an SSRI antidepressant simultaneously, wherein the dose of risperidone does not have to be adjusted based on the dose of the SSRI administered.
[0020] There is also a need in the art for improved methods of treating the first onset or relapse of schizophrenia, particularly methods of treating acute exacerbations of schizophrenia. A major advance in the art is the provision of an improved method for first-line treatment of acute exacerbations of schizophrenia using a sustained-release injection composition comprising risperidone without the need for oral supplementation of risperidone or a loading dose of risperidone in the sustained-release injection composition, wherein the composition can provide therapeutically effective blood levels of risperidone within 8-24 hours after administration, and effectively treat acute episodes within about 8 days or about 15 days after administration, while the psychotic patient is also receiving SSRI antidepressant treatment. A further improvement in the art is the provision of a method for treating acute exacerbations of schizophrenia that requires a reduced dose of a risperidone sustained-release injection composition, because the reduced dose will reduce the incidence of drug-related adverse events (side effects) on a dose-equivalent basis compared to other known risperidone LAI reservoir compositions, and will reduce the level of interaction with SSRI antidepressants. Summary of the invention
[0021] The present invention is directed to an improved composition for treating a risperidone or paliperidone-sensitive disease, disorder or condition in a subject who is concurrently treated with a CYP2D6 (cytochrome P450 2D6) enzyme inhibitor (such as an SSRI antidepressant). In some embodiments, the subject is being treated for depression and a risperidone-sensitive disease, disorder or condition.
[0022] The present invention includes an injectable depot composition, an implant formed from the injectable depot composition, a method of forming (preparing) the implant, a kit comprising components for forming the injectable depot composition, a method of preparing the injectable depot composition, a method of delivering risperidone by administering the injectable depot composition, a method of treating risperidone and / or paliperidone (9-hydroxy-risperidone) sensitive diseases, disorders or conditions, and a method of treating CYP2D6 enzyme inhibitor sensitive diseases, disorders or conditions by administering the injectable depot composition and the CYP2D6 enzyme inhibitor. In particular, references to therapeutic, surgical or diagnostic methods in this specification should be interpreted as references to compounds, pharmaceutical compositions and agents for use in such methods.
[0023] After administration, the injectable reservoir composition provides a therapeutic level of active molecule blood concentration starting from the initial dose and lasting for at least about 28 days. There is no need for oral risperidone or paliperidone as a supplement, nor is there a need for oral risperidone or paliperidone loading doses to achieve the steady-state target blood concentration of the active molecule. Unlike the use of other long-acting injection (LAI) reservoir compositions containing risperidone, the treatment method of the present invention also has the following advantages: namely, by administering a sustained-release injection composition as defined in the present invention, the plasma concentration of the active molecule at a therapeutic level can be maintained after the oral administration regimen of risperidone is terminated. In addition, unlike the use of other LAI reservoir compositions containing risperidone, the treatment method of the present invention also has the following advantages: namely, by taking a once-daily dose of risperidone orally, the plasma concentration of the active molecule at a therapeutic level can be maintained after the administration regimen of the sustained-release injection composition is terminated. The active molecule can reach therapeutic levels from the first day to the last day of the administration period.
[0024] Compared with the use of other LAI reservoir compositions containing risperidone, the method of the present invention: a) can more quickly reach and maintain therapeutic levels of active molecule (risperidone and its metabolite 9-hydroxy-risperidone, if present) blood concentration; b) can greatly improve clinical efficacy (therapeutic results). Unlike the use of other LAI reservoir compositions containing risperidone, the treatment method of the present invention also has the following advantages: that is, by administering the sustained-release injection composition defined in the present invention, the therapeutic level of active molecule blood concentration can be maintained after the risperidone oral administration regimen is terminated.
[0025] The present invention adopts a dosing regimen of about 75-100 mg, about 25-75 mg, or about 75 mg of risperidone (contained in the sustained-release injection composition described herein) injected intramuscularly once every about 28 days. There is no need to supplement risperidone orally as in RISPERDAL CONSTA (as disclosed in NDAN021346). Unlike RISPERDAL CONSTA and PERSERIS (as disclosed in NDA N210655), the present invention provides a therapeutically effective risperidone blood concentration from the first day of administration (within 2-24 hours or within 8-24 hours after administration) and lasts for about 27-31 days, about 28-31 days, or about 27-29 days. In addition, unlike the use of other LAI reservoir compositions containing risperidone, the treatment method of the present invention also has the following advantages: namely, by taking risperidone orally once a day, the blood concentration of the active molecule (risperidone and / or paliperidone) at a therapeutic level can be maintained after the sustained-release injection composition administration regimen is terminated.
[0026] The sustained-release injection composition of the present invention can be used for subjects who are receiving CYP2D6 (cytochrome P450 2D6) enzyme inhibitors. The present invention provides a method for treating risperidone-sensitive diseases, disorders or conditions in subjects receiving CYP2D6 enzyme inhibitors, the method comprising administering a sustained-release injection composition to the subject by intramuscular injection, the composition comprising about 75 mg risperidone, DMSO and PLGA copolymer. In a preferred embodiment, after administration of the CYP2D6 enzyme inhibitor, the dose of the sustained-release injection composition remains unchanged (approximately the same during the treatment period), and the sustained-release injection composition is administered at least about once every four weeks.
[0027] The CYP2D6 enzyme inhibitor may also be administered to the subject after the administration of the sustained-release injection composition. Therefore, the present invention provides a method for treating a risperidone-sensitive disease, disorder or condition and a CYP2D6 enzyme inhibitor-sensitive disease, disorder or condition in a subject, the method comprising: a) administering to the subject a dose of a long-acting injection (LAI) reservoir composition comprising about 75 mg of risperidone, DMSO and a PLGA copolymer by intramuscular injection; b) administering to the subject a dose of the CYP2D6 enzyme inhibitor within 2 to 4 weeks after administration. In a preferred embodiment, the dose of the sustained-release injection composition remains unchanged (approximately the same) during the treatment period after administration of the CYP2D6 enzyme inhibitor, and the sustained-release injection composition is administered approximately once every four weeks.
[0028] The present invention also provides a method for converting a once-daily oral risperidone dosage regimen to a once-every-28-day risperidone sustained-release injection composition dosage regimen in a subject receiving oral risperidone and a CYP2D6 enzyme inhibitor, the method comprising: a) stopping the oral administration of risperidone once a day to a subject in need thereof; b) within 24-48 hours or within 24 hours after discontinuation of the drug, injecting the subject with the sustained-release injection composition described herein, the composition comprising about 75 mg of risperidone, thereby maintaining a therapeutically effective blood concentration of the active molecule in the subject for about 28 days. In some embodiments, if the subject's oral dose of risperidone once a day is less than 4 mg, a dose of the sustained-release injection composition described herein is administered to the subject, which contains up to (or no more than) about 75 mg of risperidone. In other embodiments, if the subject's oral dose of risperidone once a day is 4 mg or more and / or up to 6 mg, a dose of the sustained-release injection composition described herein is administered to the subject, which contains no more than about 75 mg of risperidone. In some embodiments, the CYP2D6 dosage is not changed upon initiation of treatment with the extended release injectable composition.
[0029] The present invention also provides a method for converting an oral risperidone dosing regimen to a risperidone long-acting injection (LAI) composition dosing regimen in a subject receiving oral risperidone and a CYP2D6 enzyme inhibitor, the method comprising: a) determining a subject taking oral risperidone; b) stopping oral risperidone; and c) injecting a dose of a sustained-release injection composition containing about 75 mg of risperidone into the subject intramuscularly approximately every four weeks or approximately every month. In some embodiments, the first dose of the sustained-release injection composition is administered within 24-48 hours or within 24 hours after discontinuation of the drug. The oral dose of risperidone for the subject may be less than about 4 mg per day, or may be from about 4 mg per day to about 6 mg per day, or to about 8 mg per day. In some embodiments, the CYP2D6 dose does not change due to cessation of treatment with the sustained-release injection composition.
[0030] The CYP2D6 enzyme inhibitor can be administered in one or more separate dosage forms. In some embodiments, the CYP2D6 enzyme inhibitor is a selective serotonin reuptake inhibitor (SSRI) antidepressant. The SSRI can be selected from the group consisting of paroxetine (or its salt) and fluoxetine (or its salt). The subject taking the SSRI may be receiving treatment for depression, panic attacks, obsessive-compulsive disorder (OCD), severe premenstrual syndrome (premenstrual mood disorder), anxiety disorders (social anxiety and / or general anxiety), post-traumatic stress disorder, bulimia nervosa, major depressive disorder, panic disorder, depressive disorder associated with bipolar I disorder, or refractory depression (depression that has not improved after treatment with at least two other methods).
[0031] The present invention provides a dosing regimen suitable for a subject receiving a CYP2D6 enzyme inhibitor such as an SSRI (and a sustained-release injection composition containing risperidone). Listed below are examples of CYP2D6 enzyme inhibitors that can be administered to a subject receiving a sustained-release injection composition containing risperidone.
[0032]
[0033] The present invention provides a method for treating risperidone or paliperidone-sensitive psychiatric disorders in a subject in need thereof, the method comprising administering a dose of the sustained-release injection composition described herein to the subject by intramuscular injection, wherein the subject is also receiving SSRI antidepressant treatment, and the dose of the sustained-release injection composition contains about 75 mg of risperidone. In some embodiments, the SSRI is PEG2000 (or PEG-2K).
[0034] According to one aspect of the present invention, the initial dose of the sustained-release injection composition is the same strength as its maintenance dose. For example, for a subject receiving a sustained-release injection composition containing an initial dose of about 75 mg of risperidone, the second and subsequent maintenance doses of the sustained-release injection composition will contain about 75 mg of risperidone. Therefore, in an embodiment of the present invention, the risperidone dosage concentration in the sustained-release injection composition administered to the subject remains substantially unchanged throughout the treatment period in which the subject is simultaneously treated with a CYP2D6 enzyme inhibitor.
[0035] A preferred embodiment of the present invention provides a method for treating a risperidone or paliperidone-sensitive disease, disorder or condition and an SSRI-sensitive disease, disorder or condition in a subject, the method comprising (in no particular order): a) administering to the subject a sustained-release injectable composition containing risperidone as defined herein, the composition containing a dose of no more than about 75 mg of risperidone; and b) administering to the subject a therapeutically effective dose of an SSRI.
[0036] In some embodiments, prior to administration of the sustained-release injection composition, the subject: a) has an unstable mental state and develops moderate to severe psychotic symptoms; b) experiences an acute exacerbation of schizophrenia for the first time; c) is receiving one or more oral antipsychotics; d) has previously experienced one or more acute exacerbations of schizophrenia; e) has worsening psychotic symptoms or is about to relapse; d) has experienced one or more acute exacerbations of schizophrenia; e) is experiencing worsening psychotic symptoms or is about to relapse; f) is experiencing a recurrence of moderate to severe psychotic symptoms; and / or g) is receiving treatment with a sustained-release injection composition not described in the present invention.
[0037] In some embodiments: a) the sustained-release injection composition contains about 75 mg of risperidone, DMSO and PLGA copolymer; b) after administration, the sustained-release injection composition forms a biodegradable implant in the muscle; c) before administration, ≤2.5%, ≤5%, ≤7.5%, ≤10%, ≤20% of risperidone is dissolved in the sustained-release injection composition; d) before administration, >0%, ≥0.5%, ≥1%, ≥5%, ≥10%, ≥15% or up to about 20% of risperidone by weight is dissolved in the composition; e) the ratio of lactic acid monomer to glycolic acid monomer in the PLGA copolymer is in the range of about 50:50 to about 75:25, about 35:65 to about 75:25, about 45:55 to about 70:30, about 50:50 to about 65:35, or about 65:35 to about 75:25, 45:55 to 55:45, or 48:52 to 52:48, or about 50:50, i.e., 50:50±10%, or 75:25±10%; f) before administration, the polymer used to form the sustained release injection composition The viscosity of the polymer solution ranges from about 0.5-7 Pa.s, about 0.5-4 Pa.s, about 0.7-4 Pa.s, about 0.5-3.0 Pa.s, about 0.7-3.0 Pa.s, about 1.5-2.1 Pa.s±10%, about 1.5 to about 2.5 Pa.s, about 1.5 to about 2.3 Pa.s, or about 1.7-1.8 Pa.s±10%; g) the PLGA copolymer has a viscosity of about 0.20-0.60 dl / g, about 0.30-0.55 dl / g, about 0.3 6-0.52 dl / g, about 0.40-0.58 dl / g or about 0.46-0.51 dl / g, measured at a concentration of 0.5% (weight percentage) in chloroform at 30° C. using an Ubbelohde 0b glass capillary viscometer; h) the weight ratio of DMSO to risperidone in the sustained-release injection composition is about 5:1 to about 4:1, about 4.6:1 to about 4.8:1, about 4.6:1 to about 4.7:1, about 4.67:1, about 4.66:1 or about 4.68:1, or about 4.66:1; i) the weight ratio of risperidone to (PLGA+risperidone) in the sustained-release injection composition (expressed as the weight of risperidone as a percentage of the weight of risperidone plus PLGA) is in the range of about 15-40%, about 25-35%, about 30-35%, about 31-35%, about 32-34% or about 33%; j) the PLGA copolymer is terminated with an ester group or a carboxyl group; k) the content of risperidone in the preparation is about 10-15%, about 15-20%, about 15-30%, about 15-40%, about 15-50%, about 15-60%, about 15-70%, about 15-80%, about 15-90%, about 15-100%, about 15-110%, about 15-120%, about 15-130%, about 15-140%, about 15-150%, about 15-160%, about 15-170%, about 15-180%, about 15-200%, about 15-210%, about 15-230%, about 15-240%, about 15-250%, about 15-260%, about 15-270%, about 15-280%, about 15-290%, about 15-30 ... about 11-14%, about 12-14% or about 13%; l) risperidone is partially dissolved or substantially incompletely dissolved in the composition; m) the PLGA polymer is irradiated with β or γ rays, preferably in the range of 10-30 kGy, more preferably in the range of 15-30 kGy, and most preferably in the range of 16-25 kGy ± 10%; n) the sustained-release injection composition is sterile; o) the sustained-release injection composition is effective for at least four weeks from the date of administration. p) before administration, the viscosity of the sustained-release injection composition is in the range of about 1.0-7.0 Pa.s, about 1.5-7.0 Pa.s or about 1.8-6.5 Pa.s; q) the weight ratio of the solvent (DMSO) to the polymer solution (expressed as the percentage of the weight of the solvent to the weight of the polymer plus the solubilizing agent) is about 50-75%, about 65-75%, about 60-70%, about 68-7 2% or about 70%; r) the concentration of PLGA in the sustained-release injection composition is in the range of 24-50%, 24-40%, 24-30%, 25-27% or 26% (expressed as a percentage of the weight of the polymer to the total weight of the composition); and / or s) based on the total weight of the sustained-release injection composition, the content of DMSO in the injectable reservoir composition is about 55-65%, about 57-63%, about 60-62% or about 61% by weight. .
[0038] For a 75 mg drug dosage strength, an exemplary kit may include about 90 mg (or about 75-105 mg or about 80-100 mg or about 85-105 mg or about 85-95 mg) of drug (risperidone, paliperidone, or a mixture thereof), about 420 mg (or about 405-435 mg or about 415-425 mg) of DMSO, and about 180 mg (or about 165-200 mg or about 170-190 mg or about 175-185 mg) of PLGA having a L:G monomer molar ratio of about 45:55 to about 55:45 (or about 50:50).
[0039] In some embodiments, before administration, the sustained-release injection composition comprises about 75 mg (or about 65-85 mg or about 70-80 mg) of drug, DMSO and PLGA, wherein the content of the drug is about 10-15% by weight, the content of DMSO is about 55-65% by weight, the content of PLGA is about 24%-30% by weight, and the L:G monomer molar ratio of PLGA is about 45:55 to 55:45.
[0040] In some embodiments, before administration, the sustained-release injection composition comprises about 75 mg (or about 65-85 mg or about 70-80 mg) of drug, DMSO and PLGA, wherein the content of the drug is about 12-14% by weight, the content of DMSO is about 57-63% by weight, the content of PLGA is about 25-27% by weight, and the L:G monomer molar ratio of PLGA is about 45:55 to 55:45.
[0041] For a 100 mg drug dosage strength, an exemplary kit may include about 115 mg (or about 100-130 mg or about 105-125 mg or about 110-120 mg) of drug (risperidone, paliperidone, or a mixture thereof), about 537 mg (or about 515-560 mg or about 520-550 mg or about 530-545 mg) of DMSO, and about 230 mg (or about 215-245 mg or about 220-235 mg) of PLGA having a L:G monomer molar ratio of about 45:55 to about 55:45 (or about 50:50).
[0042] In some embodiments, before administration, the sustained-release injection composition comprises about 100 mg (or about 85-115 mg or about 90-110 mg or about 95-105 mg) of drug, DMSO and PLGA, wherein the content of the drug is about 10-15% by weight, the content of DMSO is about 55-65% by weight, the content of PLGA is about 24%-30% by weight, and the L:G monomer molar ratio of PLGA is about 45:55 to 55:45.
[0043] In some embodiments, before administration, the sustained-release injection composition comprises about 100 mg (or about 85-115 mg or about 90-110 mg or about 95-105 mg) of drug, DMSO and PLGA, wherein the content of the drug is about 12-14% by weight, the content of DMSO is about 57-63% by weight, the content of PLGA is about 25-27% by weight, and the L:G monomer molar ratio of PLGA is about 45:55 to 55:45.
[0044] In some embodiments, the step of preparing the sustained-release injection composition comprises: a) mixing DMSO with a powder mixture of PLGA and a drug for 10 minutes or less, 5 minutes or less, 4 minutes or less, 3 minutes or less, 2 minutes or less, 1 minute or less, or 30 seconds or less, thereby forming the sustained-release injection composition, wherein at least 80% of the drug by weight is suspended therein, and PLGA is completely dissolved therein. When a syringe is used as a container, the mixing of the components is achieved by connecting the syringes together and repeatedly pushing and pulling the respective pistons as needed. In some embodiments, the number of pushes of the piston is 200 times or less, 150 times or less, 100 times or less, 75 times or less, 50 times or less. Pushing refers to causing a liquid to flow from one syringe to another.
[0045] The sustained-release injection composition can be injected intramuscularly or subcutaneously, or injected into adipose tissue, preferably intramuscularly into the gluteal muscle or deltoid muscle.
[0046] In some embodiments, the treatment methods of the present invention: a) do not include the step of orally administering one or more (plural) risperidone loading doses in the sustained-release injection composition prior to administering the sustained-release injection composition by intramuscular injection; and / or b) do not include the step of orally administering one or more doses of risperidone within the 28-day or monthly period.
[0047] The composition used in the treatment method of the present invention can be provided as a kit for forming the composition. In some embodiments, the drug and the biocompatible polymer are contained in a first container, and DMSO is contained in a separate second container. Preferably, at least one of the first container and the second container is a disposable or non-disposable syringe, vial, instrument or medicine tube, and more preferably, the first container and the second container are both disposable syringes. The container can be a syringe, a vial, a capsule, an ampoule, an instrument or a medicine tube. In another embodiment, the three components are respectively contained in respective containers. In another embodiment, DMSO and risperidone are contained in a first container, and the polymer is contained in a second container. If necessary, the contents of the two containers are mixed together, for example, by moving the piston of the syringe back and forth, so that the composition of the present invention is reconstituted.
[0048] Therefore, the method of treatment may further include one or more of the following steps: a) providing a pharmaceutical kit, the pharmaceutical kit comprising at least two containers, each containing the components of the sustained-release injection composition, and mixing the contents of the at least two containers to form the composition; b) providing a pharmaceutical kit, the pharmaceutical kit comprising at least two containers, each containing the components of the sustained-release injection composition, and mixing the contents of the first container with the contents of the second container to form the composition, wherein the first container contains PLGA and risperidone, and the second container contains DMSO; c) providing a A kit comprising at least two containers, each containing ingredients of a sustained-release injection composition, and mixing the contents of a first container with the contents of a second container to form the composition, wherein the first container contains risperidone and the second container contains PLGA and DMSO; or d) providing a kit comprising a plurality of containers, each containing ingredients of a sustained-release injection composition, and mixing the contents of the plurality of containers to form the composition, wherein the plurality of containers include a first container containing risperidone, a second container containing PLGA, and a third container containing DMSO. In some embodiments, the kit comprises a single dose of risperidone.
[0049] The present invention provides a method for treating a risperidone and / or paliperidone-sensitive disease, disorder or condition, the method comprising preparing a sustained-release injection composition, and administering the sustained-release injection composition to a subject in need thereof, thereby treating the disease, disorder or condition. The method may further comprise the step of providing a pharmaceutical kit as described herein.
[0050] In some embodiments, the administration method comprises: a) providing a pharmaceutical kit comprising a container containing DMSO and a container containing a drug and PLGA, wherein the PLGA has a particle size distribution as described herein; b) preparing a sustained-release injection composition as described herein by mixing the components in the container to form the sustained-release injection composition; and c) administering the sustained-release injection composition to a subject.
[0051] In some embodiments, the method of treatment comprises: a) providing a kit comprising a container containing DMSO and a container containing a drug and PLGA, wherein the PLGA has a particle size distribution as described herein; b) preparing a sustained-release injectable composition as described herein by mixing the components in the containers to form the sustained-release injectable composition; and c) administering the sustained-release injectable composition to a subject in need thereof.
[0052] In the methods and kits described herein, DMSO, PLGA and the drug may be separately contained in two, three or more containers in the kit.
[0053] Exemplary risperidone or paliperidone sensitive diseases, disorders or conditions include, for example, psychosis, delusional psychosis, psychotic depression, obsessive-compulsive disorder, schizophrenia, bipolar disorder, schizoaffective disorder, non-schizophrenia psychosis, Asperger's syndrome, Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, personality disorder, aggression, depression, dementia, intellectual disability and behavioral disorder, mental retardation and autism, autism spectrum disorder, anxiety, eating disorders, neurotic anxiety, insomnia, idiopathic dystonia, drug abuse, and any combination thereof. The treatment of acute exacerbation of the above-mentioned diseases, disorders and conditions is within the scope of the present invention. Preferably, schizophrenia, schizoaffective disorder, bipolar disorder and bipolar mania are treated.
[0054] In some embodiments, psychosis refers to an acute psychotic episode, such as an acute exacerbation of schizophrenia, wherein the sustained-release injection composition containing risperidone according to the present invention is administered by intramuscular injection once about every 28 days, about every 28-32 days, or about every month.
[0055] The present invention includes all combinations of the aspects, embodiments and sub-embodiments described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0056] Figure 1 Shown are the mean blood concentration curves of the total active moiety (risperidone plus 9-hydroxyrisperidone) after intramuscular injection of the sustained-release injection composition at three dosage concentrations (50 mg, 75 mg and 100 mg risperidone).
[0057] Figure 2A and Figure 2B It is shown that the gluteal muscles ( Figure 2A ) and deltoid ( Figure 2B ) Mean blood concentration curve of the total active portion (risperidone plus 9-hydroxyrisperidone) after repeated intramuscular injection (once every 28 days, for a total of 4 times) of a sustained-release injection composition containing 75 mg of risperidone. DETAILED DESCRIPTION
[0058] Unless otherwise indicated, the terms "drug", "metabolite" and their prodrugs are used interchangeably. In general, the term "drug" encompasses its metabolites and prodrugs.
[0059] As used herein, the term "loading dose" refers to: a) administering a dose of a drug orally to a subject daily over a period of multiple days, wherein the loading dose is sufficient to establish a steady-state blood concentration of the active moiety within the therapeutic range in the subject; and / or b) administering one or more higher doses of a sustained-release injectable composition comprising risperidone prior to administering a maintenance dose of a sustained-release injectable composition comprising risperidone, wherein the one or more higher doses are sufficient to establish a steady-state plasma concentration of the active moiety within the therapeutic range in the subject prior to administering the maintenance dose.
[0060] As used herein, the term "maintenance dose" refers to a dose of a sustained-release injection composition comprising a dose of risperidone, wherein the dose is administered to the subject from the first (initial) administration of the sustained-release injection composition to subsequent administrations (about once every 28 days or about once a month) of the sustained-release injection composition. The maintenance dose is sufficient to establish a steady-state plasma concentration of the active portion within the therapeutic range in the subject without the need to administer a loading dose of a sustained-release injection composition comprising risperidone or oral supplementation of risperidone.
[0061] As used herein, the term "oral supplementation" means that after the sustained-release injection composition of the present invention is administered to the subject, a certain dose of risperidone is orally administered to the subject every day.
[0062] As used herein and unless otherwise indicated, the drug or active ingredient contained in the injection composition can exist in its free base, salt, amorphous, crystalline, crystalline, anhydrous, hydrated, optically pure, optically enriched or racemic form. Combinations of these different forms are also within the scope of the present invention. Prodrugs, metabolites (paliperidone) or derivatives of the drug may also be included.
[0063] In some embodiments, salt forms of risperidone can be prepared according to US Publication No. 20040266791, the relevant disclosure of which is incorporated herein by reference; however, other known salts can also be used.
[0064] As used herein, the term "prodrug" refers to a compound that is administered in an inactive (or not fully active) form and subsequently converted to an active agent by normal metabolic processes. The prodrug acts as a "precursor" of a desired drug (e.g., risperidone, paliperidone or other drug).
[0065] As used herein, the term "derivative" refers to a compound obtained by chemically modifying a parent compound, such "derivative" contains almost all or the entire chemical structure of the parent compound (or base). A derivative is a compound formed from a similar compound, or it can be imagined that if one atom is replaced by another atom or group of atoms, another compound will be produced. A derivative is a compound derived or obtained from another compound, containing the basic elements of the original substance. A derivative is a compound that can be generated from another structurally similar compound by one or more steps.
[0066] As used herein, the term "dosing period" refers to the number of days or weeks from the initial date after dosing to at least 28 days after dosing or to the next dosing date. During the dosing period, the implant will provide a therapeutic level of blood drug concentration for about 4 weeks or longer. The dosing period can be terminated after the predetermined number of days expires or the blood drug concentration is below the therapeutic level.
[0067] As used herein, a "treatment period" refers to the number of weeks, months, or years that a subject is treated with the LAI reservoir composition of the present invention (forming a respective implant). A treatment period generally includes multiple dosing periods. During treatment, the dosing periods may be continuous or in an overlapping manner. For example, a first dose of an injectable composition is administered, and a second dose of an injectable composition may be administered at a time after the first dose is administered, so that each dose has its corresponding dosing period, and these dosing periods overlap. Dosing periods are typically continuous, or overlap by no more than one to two, three, four, five, six, or seven days.
[0068] The present invention employs a risperidone-containing composition suitable for forming one or more in situ intramuscular implants, which can maintain the desired blood concentration of active molecules (risperidone and / or paliperidone) for about 28 days or 28+ / -5 days or 28+ / -4 days or 28+ / -3 days or 28+ / -2 days or 28+ / -1 day or about 26-33 days or about 28-33 days. In addition, the composition also has better pharmaceutical properties. As used herein, the term "implant" refers to a composition based on the formation of a solid stable polymer matrix system that can entrap drug particles. This term is used to avoid confusion with the term "microparticles", which generally refers to denatured polymer microparticles obtained by solvent evaporation or spray drying techniques. The composition of the present invention contains drug particles suspended in a polymer solution, and when injected, as the solvent diffuses and the polymer precipitates to form a matrix containing drug particles, these drug particles are entrapped in situ in the solid polymer matrix. As used herein, the term "implant" refers to a reservoir composition (sustained-release reservoir), because the composition of the present invention is an injectable reservoir composition, in particular a sustained-release injection composition that forms a sustained-release reservoir when injected. The sustained-release injection composition is also considered to be an injection suspension (or sustained-release injection composition), which comprises risperidone particles suspended in DMSO and PLGA polymer solution, wherein the sustained-release injection composition forms a sustained-release reservoir (implant) after administration.
[0069] Intramuscular doses can be administered to any muscle or muscle group that the pharmaceutical industry generally considers suitable for injectable compositions. In some embodiments, the composition is injected through the gluteal muscles and / or deltoid muscles. The composition can also be injected through the quadriceps muscle group. The dose can be administered to a single muscle site or divided into two or more parts and administered to two or more muscle sites of the subject. For example, the first part of the dose can be administered to a first site of the gluteal muscle of the subject, and the second part of the dose can be administered to a second site of the gluteal muscle of the subject. The injectable composition can be injected into one or more injection sites of the subject on the same day and still be considered as part of the same administration period. For example, a partial dose can be injected at a first injection site and another identical dose can be injected at another injection site. A single implant will be formed at each injection site. This single-day administration is considered a single dose, single administration period administration. Alternatively, the administration can be modified to insert the needle into multiple injection sites under the skin of the subject, which can be achieved by first inserting the skin and muscle and applying a portion of the dose, then partially withdrawing the needle and turning it to another part of the muscle, while leaving the needle tip under the skin, and then injecting another portion of the dose into the muscle. This administration is still considered a single dose within a single dosing period.
[0070] A therapeutically effective amount of an injectable composition refers to the amount of an injectable composition containing a specific dose of a drug. Therefore, an injectable composition with a therapeutically effective amount of 75-100 mg contains a risperidone dose of 75-100 mg; therefore, the actual dosage of the sustained-release injectable composition will be greater than 75-100 mg, and the actual dosage of the injectable composition is determined by the drug content in the sustained-release injectable composition. For example, a therapeutically effective amount of a sustained-release injectable composition contains 75 mg of risperidone, wherein the content of risperidone is about 13% by weight, which is equivalent to a therapeutically effective amount of about 577 mg, and the composition contains DMSO, risperidone and PLGA. Similarly, a therapeutically effective amount of a sustained-release injectable composition contains 100 mg of risperidone, wherein the content of risperidone is about 13% by weight, which is equivalent to a therapeutically effective amount of about 769 mg, and the composition contains DMSO, risperidone and PLGA.
[0071] Although not necessary, the injection composition of the present invention may further include an alkali agent. A low water-soluble alkali agent may be included, such as less than 0.02 mg / mL. The molar ratio of the alkali agent may be greater than 2 / 5 (drug / alkali agent), i.e., the molar ratio of the alkali agent exceeds the drug. A preferred alkali agent is an alkali or alkaline earth hydroxide, such as magnesium hydroxide or aluminum hydroxide. Due to the limited water solubility of the alkali agent, for example, the particle size distribution d0.5 of magnesium hydroxide is preferably less than 10 μm.
[0072] The treatment method of the present invention can use a suitable kit for forming a biodegradable solid implant in situ in a subject in need thereof. In some embodiments, the kit comprises: a first container containing risperidone; a second container containing a biocompatible PLGA copolymer; and a third container containing DMSO. A polymer solution is formed by mixing the contents of the third container with the contents of the second container, and then the polymer solution is mixed with the contents of the first container to form an injection composition as described herein. In some embodiments, the copolymer and the drug (and / or its metabolites and / or prodrugs) are contained in the first container, and DMSO is contained in the second container. In some embodiments, the drug (and / or its metabolites and / or prodrugs) are contained in the first container, and PLGA and DMSO are contained in the second container. In some embodiments, the container is a syringe, and the mixing of its contents can be achieved by pushing the syringe piston back and forth after direct or indirect connection. Embodiments of the invention include: a) the drug and / or copolymer are present in a solid form in the container prior to mixing with the solvent; or b) the drug and / or copolymer are present in a granular form or lyophilisate form in the container prior to mixing with the solvent (DMSO).
[0073] In some embodiments, the injectable depot composition is provided in a ready-to-use form and is stored in a single container at room temperature or under refrigerated conditions. The ready-to-use form can be provided in a single dose or multiple doses.
[0074] The sustained-release injection composition can be prepared by mixing a polymer solution with risperidone. As used herein, the term "polymer solution" refers to a fluid composition composed of DMSO and a polymer dissolved therein. In some embodiments, at least 80%, at least 90%, at least 95%, at least 99% or all of the polymer is dissolved in DMSO. Unless otherwise indicated, the viscosity value of the polymer solution or injection composition is expressed in Pa.s.
[0075] Unless otherwise stated, the viscosity values of polymer solutions or injection compositions are expressed in Pa.s. The viscosity range of polymer solutions is: about 0.5 to about 3.0 Pa.s, about 0.7 to about 3.0 Pa.s, about 0.7 to about 2.0 Pa.s, about 1.5 to about 2.5 Pa.s, about 1.5 to about 2.3 Pa.s, about 1.5 to about 2.1 Pa.s, 1.5-2.1 ± 10% Pa.s, 1.6-1.9 ± 10% Pa.s or 1.7-1.8 ± 10% Pa.s. Before administration, the viscosity of the sustained-release injection composition is in the range of about 1.0-7.0 Pa.s, about 1.5-7.0 Pa.s or about 1.8-6.5 Pa.s. In some embodiments, these values can vary within the range of about ± 10% of the specified limits. Viscosity can be controlled primarily as a function of polymer molecular weight (intrinsic or intrinsic viscosity) and polymer concentration in the injection composition.
[0076] In some embodiments, the weight ratio of the polymer solution to the drug (expressed as the weight ratio of (polymer + solvent) to the drug) is about 15:1 to about 5:1, about 12:1 to about 5:1, about 7:1 to about 6.5:1, about 6.5:1 to about 6.8:1, about 6.67:1, about 6.66:1, or about 6.68:1.
[0077] In some embodiments, the weight ratio of polymer to polymer solution (expressed as a percentage of polymer weight to polymer solubilizing agent weight) is about 25-50%, about 25-35%, about 30-40%, about 28-32%, or about 30%.
[0078] In some embodiments, the weight ratio of solvent (DMSO) to polymer solution (expressed as a percentage of the weight of solvent to the weight of polymer plus solvent) is about 50-75%, about 65-75%, about 60-70%, about 68-72%, or about 70%.
[0079] The LAI depot composition used in the treatment method of the present invention may comprise at least one polymer (or copolymer), DMSO and risperidone, and may further comprise one or more pharmaceutical excipients suitable for intramuscular injection.
[0080] After intramuscular injection, the sustained-release injection composition forms a solid implant in situ in the muscle tissue. When the implantable composition contacts body fluids or water, the solvent (DMSO) will diffuse from the polymer-drug mixture, and the polymer will precipitate, so that when the composition solidifies into a monomer implant at the injection site, the drug is trapped or encapsulated in the polymer matrix. Drug release follows the general characteristics of drug diffusion or dissolution from the polymer matrix. The drug can also be released by erosion / degradation of the polymer. The drug (active ingredient) forms a suspension or dispersion in a biodegradable and biocompatible polymer solution to form an injection composition that can be injected by a syringe (or pump) and a needle. In some embodiments, the implant begins to release risperidone within about 2 hours after administration, with rapid onset (e.g., less than 1 day, less than 18 hours, less than 12 hours, less than 6 hours, less than 3 hours), and lasts for at least 4 weeks. From the first day of administration, it is possible to provide a therapeutically effective blood level of active molecules (risperidone + 9-hydroxy-risperidone), and lasts for at least 4 weeks.
[0081] As used herein, the expression "about 50:50" refers to the ratio of lactic acid to glycolic acid monomers in a biocompatible PLGA copolymer based on lactic acid and glycolic acid, and the standard error of the technique used to measure the monomer ratio in the present invention is ±10%. It is known that the actual monomer ratio of commercially available PLGA copolymers varies slightly, but they may indicate a monomer ratio of 50:50. For example, a copolymer indicated as having a monomer ratio of 50:50 may actually have a monomer ratio between 45:55 and 55:45 or between 48:52 and 52:48. Therefore, as long as the monomer ratio is specified as "50:50" or "about 50:50" in the present invention, it means that all monomer ratios between 45:55 and 55:45 can be considered interchangeable.
[0082] The composition of the present invention comprises a biodegradable polylactic acid-polyglycolic acid copolymer. The ratio of lactic acid to glycolic acid monomers (L:G) in the polymer can range from about 35:65 to about 75:25, from about 50:50 to about 75:25, from about 45:55 to about 70:30, from about 50:50 to about 65:35, or from about 65:35 to about 75:25, or 50:50±10% or 75:25±10%.
[0083] The intrinsic viscosity can be measured using an Ubbelohde 0C or 0B glass capillary viscometer ( The viscosity of the PLGA copolymers is measured at a concentration of 0.1% w / v or 0.5% w / v in chloroform at 25° C. or 30° C. using a Cannon-Fenske No. 25 glass capillary viscometer. PLGA copolymers of suitable grades (based on molecular weight, intrinsic viscosity and / or molar ratio of lactic acid to glycolic acid monomers) as described herein, end-capped (such as with ester groups, e.g., dodecyl esters, methyl esters), can be obtained from (Essen, Germany), Boehringer Ingelheim (Ingelheim am Rhein, Germany), ALKERMES (Dublin, Ireland), or SIGMA ALDRICH (St. Louis, Missouri), and sold under the trade name LAKESHORE BIOMATERIALS TM or Because the composition of some grades of end-capped PLGA is proprietary, the properties of the ester end caps are not disclosed. Nevertheless, the performance properties of the various grades of PLGA copolymers described in the present invention are known and can be used to characterize the material.
[0084] For the purposes of the present invention, in this specification, the intrinsic viscosity or inherent viscosity (η inh ) is defined as the relative viscosity η r The ratio of the natural logarithm of the polymer weight concentration c, that is:
[0085] η inh =(lnη r ) / c
[0086] Relative viscosity (η r ) is the solution viscosity η and the solvent viscosity η s The ratio is:
[0087] η r =η / η s
[0088] Unless otherwise specified, the intrinsic viscosity values and molecular weight values in this specification should be understood as being measured according to the steps described in Example 1 (step A and / or step B). As is generally accepted in the art, the intrinsic viscosity value is considered herein as an indirect indicator of the molecular weight of the polymer. Therefore, when the monomer and end group composition are the same, a decrease in the intrinsic viscosity of a polymer measured at a given concentration in a given solvent indicates a decrease in the molecular weight of the polymer (IUPAC. Basic definitions of terms relating to polymers 1974. Pure Appl. Chem. 40, 477-491 (1974)).
[0089] The inherent viscosity of the PLGA polymer in the sustained release injection composition can range from about 0.20-0.60 dl / g, about 0.30-0.55 dl / g, about 0.36-0.52 dl / g, about 0.40-0.58 dl / g or about 0.46-0.51 dl / g, measured using an Ubbelohde No. 0b glass capillary viscometer at 30° C. in chloroform at a concentration of 0.5% (weight percent).
[0090] The weight average or average molecular weight of the PLGA polymer in the sustained release injectable composition may be about 27-47 kDa, about 31-43 kDa, about 31-40 kDa, about 30-46 kDa, or about 30-36 kDa.
[0091] The PLGA polymer can be irradiated with beta or gamma rays at a dose of about 10 to about 30 kGy at -40°C to +35°C. Irradiation can reduce the molecular weight of the PLGA polymer and / or sterilize it. In some embodiments, the irradiation temperature of the polymer is below 35°C, more preferably below 25°C, and most preferably below 8°C. In a preferred embodiment of the present invention, the biocompatible copolymer is irradiated with gamma or beta rays, with an irradiation dose range of 10-30 kGy ± 10% and an irradiation temperature of -40°C to +35°C to adjust its molecular weight to a range of about 27-47 kDa, about 31-43 kDa, about 31-40 kDa, about 30-46 kDA, or about 30-36 kDa. In a more preferred embodiment of the present invention, the polymer is irradiated at a dose of 15-25 kGy ± 10% at 8°C.
[0092] The concentration of the polymer component in the composition of the present invention can be in the range of 20-50%, 24-50%, 24-34%, about 24-30%, about 25-27%, or about 26% (expressed as a percentage of the weight of the polymer to the total weight of the formulation). In some embodiments, at least 80%, at least 90%, at least 95%, at least 99%, or all of the polymer is dissolved in DMSO or the injectable composition.
[0093] In some embodiments, the drug content ranges from about 4% to about 16%, about 7% to about 15%, about 10% to about 15%, about 12% to about 14%, or about 13% by weight.
[0094] After administration, the injection composition forms an implant that provides a well-controlled release curve for the drug. A "well-controlled" release curve means that the initial release curve of the implant cannot be too steep (fast), otherwise it will lead to excessive blood drug concentration and accompanied by toxic side effects; the initial release curve cannot be too flat (slow), otherwise it will lead to blood drug concentrations below the therapeutic concentration. Within 24 hours of placement in an aqueous environment, an implant showing a well-controlled initial release curve will release no more than 20%, no more than 15%, no more than 12%, no more than 10%, no more than 8%, no more than 6%, no more than 5%, no more than 4%, no more than 3%, no more than 2% or no more than 1% by weight. After being placed in an aqueous environment for 24 hours, the drug release will be at least 0.1%, at least 0.5%, at least 1%, at least 2%, at least 3% or at least 4% by weight. The present invention includes all combinations of embodiments of the present invention.
[0095] The blood concentration curve during the administration period may show one, two or more maxima and one, two or more minima. The initial maximum may be caused by a slowing release rate after the drug dissolves during the first few days of the administration period, while another maximum may be caused by an accelerated release rate during the remaining days of the administration period. Embodiments of the present invention include: a) the blood drug concentration curve shows a maximum value in the first 6 days, the first 3 days, the first 2 days, or the first 1 day or 2 days of the dosing period; b) the blood drug concentration curve shows a maximum value in the last 10 to 24 days of the 4-week dosing period; c) the blood drug concentration curve shows a maximum value in the first few days of the dosing period, and the blood drug concentration shows a maximum value in the remaining days of the dosing period; d) the blood drug concentration curve is basically flat during the dosing period (the standard deviation is within ±30%, ±25%, ±20%, ±15%, ±10% or ±5% of the mean or median); e) the blood drug concentration curve reaches a peak value in the first 48 hours or the first 72 hours or the first 24 to 48 hours of the dosing period; and / or f) the blood drug concentration curve reaches a peak value in the last 10 to 28 days or the last 18 to 25 days of the 4 to 5 week dosing period.
[0096] In humans, when the dosage of the injection composition is equivalent to a dose of about 20-80 mg, about 37.5-125 mg, or about 50-100 mg risperidone, the average blood concentration of the active molecule (risperidone + 9-hydroxy-risperidone) may be about 3-200 ng / mL, about 5-80 ng / mL, or about 10-60 ng / mL. When the dosage of the injection composition is equivalent to a dose of about 25-150 mg, about 37.5-125 mg, or about 50-100 mg risperidone, the average minimum blood concentration during administration is in the range of about 1-80 ng / mL, 5-50 ng / mL, or about 5-40 ng / ml. When the dosage of the injection composition is equivalent to about 25-150 mg, about 37.5-125 mg or about 50-100 mg of risperidone, the average blood peak concentration during administration is in the range of about 8-300 ng / mL, 10-150 ng / mL or 10-120 ng / mL. Due to poor health, advanced age, impaired metabolism, renal failure, disease, etc., the blood concentration of some subjects on the basis of the equivalent dose may exceed the range specified in the present invention. However, in the patient population injected with the implant, the blood concentration of most subjects is within the range specified in the present invention.
[0097] As used herein, drug blood concentration includes the sum of blood concentrations of the drug and its active metabolites. For example, whenever risperidone blood concentration is mentioned, the sum of blood concentrations of risperidone and its active metabolites (such as 9-hydroxy-risperidone (paliperidone)) is included.
[0098] In some embodiments, the particle size distribution of the drug particles is as follows: the drug particles with a particle size less than 10 μm do not exceed 10% of the total volume (based on applying the Fraunhofer theory to the volume equivalent diameter of irregularly shaped particles; measured by laser light scattering, such as using a Malvern Mastersizer 2000), and the drug particles with a particle size greater than 225 μm (or 235 μm) do not exceed 10% of the total volume. In addition, the d0.5 value of the drug particles is preferably in the range of about 60-130 μm. Therefore, in some embodiments, risperidone has a wide particle size distribution, which can be unimodal, bimodal or trimodal.
[0099] In some embodiments, the drug exhibits one of the following particle size distributions:
[0100] parameter I II III IV V VI d0.1(μm) 27.49 <30 17.41 ≤20 ≤10 ≤10 d0.5(μm) 79.90 40-130 51.61 40-130 40-130 40-130 d0.9(μm) 176.66 >170 175.32 >170 >225 or >235 >200
[0101] In a preferred embodiment of the present invention, the drug has the following particle size distribution:
[0102] - particles with a size less than 10 μm do not exceed 10% of the total volume;
[0103] - no more than 10% of the total volume contains particles with a size greater than 225 μm (or 235 μm), or no more than 10% of the total volume contains particles with a size greater than 200 μm; and
[0104] - The particle size distribution has a d0.5 in the range of about 60-130 μm, about 40-90 μm or about 40-130 μm.
[0105] Particle size distribution was determined by wet laser diffraction using a light scattering technique.
[0106] Embodiments of the present invention include: a) before mixing with a solvent, risperidone is present in a solid form in a container; b) before mixing with a solvent, risperidone is present in a granular form or a lyophilized form in a container; c) the particle size distribution of risperidone is as follows: the drug particles with a particle size of less than 10 μm do not exceed 10% of the total volume, and the drug particles with a particle size of greater than 225 μm (or 235 μm) do not exceed 10% of the total volume; d) the range of d0.5 in the particle size distribution is about 60-130 μm; e) the polymer in the injection composition is The weight ratio of the polymer solution (polymer + solvent) to risperidone ranges from about 15:1 to 5:1; f) the weight ratio of the solvent to risperidone in the injectable composition (mg solvent / mg risperidone) ranges from about 12:1 to 4:1; g) the kit further comprises an alkaline agent; h) the molar ratio of risperidone to the alkaline agent ranges from 2 / 3 to 2 / 5; i) the solvent, polymer solution, risperidone and / or the injectable composition are sterilized prior to administration; and / or j) the kit further comprises an alkaline agent in one or two containers.
[0107] Other parameters, such as the weight ratio of drug to polymer solution (polymer + solvent), the weight ratio of drug to (polymer + drug), the weight ratio of solvent to drug, the weight ratio of polymer to polymer solution (polymer + solvent), the weight ratio of solvent to polymer solution (polymer + solvent), and the weight ratio of solvent to polymer solution (polymer + solvent), may also help control the initial release and / or sustained release of the drug in the compositions of the present invention.
[0108] In some embodiments, the drug is partially suspended in the composition and has a solubility in DMSO of less than about 10 mg / mL. In some embodiments, the drug is partially dissolved or substantially incompletely dissolved in a solvent, DMSO, polymer solution, or injectable composition. In some embodiments, ≤2.5%, ≤5%, ≤7.5%, ≤10%, ≤20%, or <25% of the drug is dissolved in a solvent or polymer solution to form an injectable composition. In some embodiments, by weight percentage, >0%, ≥0.5%, ≥1%, ≥5%, ≥10%, or ≥15%, or up to about 20% of the drug is dissolved in a solvent or polymer solution to form an injectable composition. All combinations of these embodiments are contemplated.
[0109] In another embodiment, the composition is a sterile composition.The polymer solution may be sterilized by sterile filtration through a filter medium having a nominal pore size of 0.22 μm or less, or by irradiation, or by a combination thereof.
[0110] The sustained-release injection composition can also be used to treat acute psychotic episodes, including delusional psychosis, psychotic depression, obsessive-compulsive disorder, schizophrenia, bipolar disorder, schizoaffective disorder, non-schizophrenic psychosis, Asperger's syndrome, Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, personality disorder, aggression, depression, dementia, intellectual disability and behavioral disorder, mental retardation and autism, autism spectrum disorder, anxiety, eating disorder, neurotic anxiety, insomnia, idiopathic dystonia, drug abuse, and any combination thereof. The injection composition can also be used as an antihistamine, for the treatment of allergic diseases, or as a prolactin secretion promoter for lactating women, or for the treatment of prolactin deficiency.
[0111] According to another aspect, the present invention provides a kit suitable for forming a biodegradable implant in situ in vivo using the composition of the present invention, wherein the drug and the biocompatible polymer are contained in a first container and the solvent is contained in a separate second container. Preferably, at least one of the first container and the second container is a disposable or non-disposable syringe, vial, instrument or medicine tube, and more preferably, the first container and the second container are both disposable syringes. This aspect relates to a kit, which includes a first container, preferably a syringe, a vial, an instrument or a medicine tube, and both are disposable or non-disposable, wherein a suitable amount of a polymer (such as PLGA) and a drug in solid form are contained; and a second container, also preferably a syringe, a vial, an instrument or a medicine tube, and both are disposable or non-disposable, wherein a water-miscible solvent is contained. If necessary, the contents of the two containers are mixed together, such as by moving the piston of the syringe back and forth, such that the composition of the present invention is reconstituted. Exemplary preferred embodiments of the present invention include syringes connected by a connecting device and syringes connected by direct threads.
[0112] According to another aspect, the present invention provides a method for administering an injectable depot composition according to the present invention to a patient experiencing an acute psychotic episode by intramuscular injection, the method comprising:
[0113] a) intramuscularly injecting a first dose of the sustained-release injection composition containing 75 mg to 100 mg of risperidone into the patient experiencing an acute psychotic episode;
[0114] b) administering to the patient an intramuscular injection of the sustained-release injection composition containing 75 mg to 100 mg of risperidone at a time point on the 28th day or the 26th day to the 31st day from the date of the last administration; and
[0115] c) Repeat step b) if necessary.
[0116] During a treatment period, the dosage of the injectable composition is usually about the same.
[0117] According to one embodiment, the weight ratio of the drug to (polymer + drug) is about 33%, the drug content accounts for about 13% of the total formulation by weight percentage, and the viscosity of the polymer and DMSO solution is in the range of 1.5-2.5 Pa.s, preferably in the range of 1.5-2.1 Pa.s, and more preferably in the range of 1.7-1.8 Pas.
[0118] According to another aspect, the present invention provides a method for intramuscularly injecting a sustained-release injection composition according to the present invention into a patient with a first attack or repeated attacks of acute exacerbation of schizophrenia, the method comprising:
[0119] a) intramuscularly injecting a first dose of the sustained-release injection composition containing 75 mg to 100 mg of risperidone into the patient experiencing an acute psychotic episode;
[0120] b) administering to the patient an intramuscular injection of the sustained-release injection composition containing 75 mg to 100 mg of risperidone at a time point on the 28th day or the 26th day to the 31st day from the date of the last administration; and
[0121] c) Repeat step b) if necessary.
[0122] A single dose is generally considered to be the amount of the composition injected into a subject over a period of no more than 24 hours, no more than 12 hours, no more than 6 hours, no more than 3 hours, no more than 1 hour, no more than 30 minutes, no more than 15 minutes, or no more than 5 minutes.
[0123] The dose can be administered to a single muscle site, or it can be divided into two or more portions and administered to two or more muscle sites of a subject. For example, a first portion of a dose can be administered to a first site of a subject's gluteal muscle, and a second portion of the dose can be administered to a second site of a subject's gluteal muscle.
[0124] As used herein, the term "initial burst" or "initial release" refers to the increase in blood levels of the drug plus active metabolites from the time the injection / administration of the injection composition to a subject in need thereof to the end of the third day after administration, which increase is also referred to as the "active portion" (risperidone and paliperidone collectively) in the present disclosure. For example, the drug can be risperidone, and its metabolite can be paliperidone. In some embodiments, the initial release period is within 3 days, within 2 days, within 1 day, within 12 hours, within 6 hours, or within 2 hours after administration.
[0125] Subjects who are receiving administration or treatment of CYP2D6 enzyme inhibitors may be administered a dose of a sustained-release injection composition containing risperidone as defined in the present invention. Typical inhibitors of CYP2D6 enzymes are divided into three categories: strong inhibitors such as bupropion, fluoxetine, paroxetine, quinidine and terbinafine; moderate inhibitors such as abiraterone, cinacalcet, duloxetine, lorcarcillin and mirabegron; and weak inhibitors such as amiodarone, celecoxib, cimetidine, clobazam, cobicistat, escitalopram, fluvoxamine, labetalol, ritonavir, sertraline, vemurafenib. The acceptable doses and dosing regimens of these compounds are well known and are described in detail in their respective drug instructions. These doses and dosing regimens are also introduced on the websites of the U.S. Food and Drug Administration (www.fda.gov) and the EMA (ema.europa.eu) and other similar agencies.
[0126] Unlike daily oral administration of risperidone, the treatment method of the present invention allows the use of a fixed dose of a sustained-release injection composition containing risperidone to treat a subject without being affected by the dose of the CYP2D6 enzyme inhibitor. In one embodiment, a sustained-release injection composition as defined in the present invention containing about 75 mg of risperidone is injected intramuscularly to a subject in need thereof. Within about 2-4 weeks after the injection, treatment of the subject with CYP2D6 is initiated. During a treatment period consisting of multiple dosing periods, the subject takes about 75 mg of the sustained-release injection composition every about 4 weeks. The CYP2D6 dose can be adjusted as needed to provide the target therapeutic effect; however, the dose of risperidone is maintained substantially at about 75 mg throughout the treatment period.
[0127] For example, an approved dosing regimen for fluoxetine (PROZAC) is exemplified below.
[0128]
[0129] The above dosage regimen may be used in conjunction with a sustained release injection composition containing about 75 mg of risperidone.
[0130] Alternatively, for a subject who is currently receiving a CYP2D6 enzyme inhibitor and has achieved a stable condition by taking 8 mg of risperidone daily, the subject is switched to a sustained-release injection composition for treatment by stopping oral risperidone and administering a sustained-release injection composition as defined in the present invention containing about 75 mg of risperidone to the subject by intramuscular injection 24 hours later. During a treatment period consisting of multiple dosing periods, the subject takes about 75 mg of the sustained-release injection composition every about 4 weeks. The CYP2D6 dose can be adjusted as needed to provide the target therapeutic effect; however, the dose of risperidone is substantially maintained at about 75 mg throughout the treatment period.
[0131] As another example, the approved dosage regimen for the immediate-release or rapid-release formulation of paroxetine (PAXIL) is as follows.
[0132]
[0133] As another example, the dosage regimen of the approved controlled-release formulation of paroxetine (PAXIL) is as follows.
[0134] Indications aldult Major depressive disorder 25 mg daily (initial dose); 25-62.5 mg daily Panic disorder 12.5 mg daily (initial dose); 12.5-75 mg daily Social Anxiety Disorder 12.5 mg daily (initial dose); 12.5-37.5 mg daily Premenstrual Dysphoric Disorder 12.5 mg daily (initial dose); 12.5-25 mg daily
[0135] SSRI antidepressants can be administered in the form of oral tablets or oral suspensions. Suitable exemplary dosage forms are described in the package inserts for PAXIL and PROZAC.
[0136] The subjects were treated with the sustained-release injection composition of Example 11 according to Example 10. During the study, 56.5% of the patients received concomitant medication. The most common drug categories were antianxiety drugs, anti-inflammatory drugs and anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and other analgesics and antipyretics. The data obtained by this study showed that the sustained-release injection composition containing risperidone and the method of use thereof according to the present invention are effective, safe and tolerable in the monthly treatment of acute schizophrenia. In terms of the main efficacy indicators, the treatment method is superior to placebo.
[0137] Risperidone was well tolerated. Observed adverse events (AEs) were consistent with expectations for oral risperidone and LAI treatment doses and were consistent with those observed in previous studies. All treatment-related adverse events (TRAEs) were predominantly mild or moderate in the majority of patients in both treatment groups. Although the incidence of TRAEs was lower in the placebo group than in the risperidone group, it was similar to the incidence reported in a similar study for acute schizophrenia and slightly lower than the incidence observed in previous LAI risperidone studies. In addition, a lower proportion of patients in both risperidone groups discontinued treatment due to TRAEs compared with placebo, and no patients died due to TRAEs during the study.
[0138] Overall, the incidence of serious TRAEs and TRAEs leading to discontinuation was low, and no significant differences were observed between treatment groups. Similarly, the incidence of ISRs (redness, swelling, or indentation) was low overall, with the highest incidence of redness in all treatment groups, and a slight dose-dependent trend for an increase in ISR. No relevant differences were observed between treatment groups in terms of 0-10 visual analog scale (VAS) scores, with a mean of 2.0 for all treatment groups, a clinically meaningful result for the new LAI formulation. Similarly, EPS, tic disorders, movement disorders, and suicidality scale scores showed no significant differences between either dose of risperidone and placebo. In addition, there were no significant differences in laboratory parameters between treatment groups from the beginning to the end of the study, with the exception of prolactin, which showed no significant changes in any of the other treatment groups. Events related to increased prolactin were one of the most frequently reported TRAEs in this study, and their incidence was comparable to that described in other studies. Several limitations should be considered when interpreting the study results.
[0139] The term "about" refers to ±20%, ±15%, ±10%, ±5%, ±2.5% or ±1% relative to a specified value, i.e., "about 20%" refers to 20±4%, 20±3%, 20±2%, 20±1%, 20±0.5% or 20±0.2%.
[0140] The technical measurement standard error (standard deviation) of all numerical values described in the present invention is ±10%.
[0141] Example
[0142] In view of the above description and the examples and claims below, those skilled in the art will be able to implement the present invention without undue experimentation. The following examples detail some methods of implementing embodiments of the present invention, and the above content can be better understood by reference to these examples. All of these examples are exemplary. These examples are not exhaustive, but only illustrate certain embodiments of the many embodiments contemplated by the present invention.
[0143] Furthermore, without limitation, in conjunction with these examples, when the dose is 2.5 mg active molecule / kg body weight, the acceptable blood concentration of the active molecule in the initial burst phase of beagle dogs is less than 75 ng / mL.
[0144] Example 1: Intrinsic Viscosity Measurement
[0145] Method A:
[0146] equipment
[0147] Triple detection (laser diffraction, viscosity measurement, refractive index) GPC chromatograph
[0148] · GPCmax VE 2001 GPC solvent / sample delivery and injection module
[0149] · TDA 305 Triple Detector Array
[0150] Reagents
[0151] GPC stabilized with 250 ppm butylated hydroxytoluene (BHT) tetrahydrofuran (THF)
[0152] Narrow distribution polystyrene standards (preferably with molecular weight around 90 or 99 kDa)
[0153] Sample preparation
[0154] 1-2mg / mL standard sample
[0155] 10 mg / mL test sample, 3 samples for each polymer to be tested
[0156] Preprocessing
[0157] Use mobile phase (tetrahydrofuran) to adjust and stabilize the chromatographic column and detector, with a working flow rate of 1 mL / min, purge the viscometer and refractive index detector, and finally check whether all signals are stable and sufficient.
[0158] Chromatographic conditions:
[0159] i-MBMMW-3078 series 2-column chromatography column (CLM1012, Viscotek)
[0160] Delay column: medium delay (CLM9002, Viscotek)
[0161] Column temperature: 30℃
[0162] Flow rate: 1mL / min
[0163] Injection volume: 100 μL
[0164] Running time: 35 minutes
[0165] Eluent: stable tetrahydrofuran (preheated to 30°C, stirred at 100 rpm)
[0166] System Check
[0167] Inject 100 μL of eluate and check if there is no response to the signal associated with the molecular weight determination.
[0168] Inject 100 μL of polystyrene standard solution to check if the measurement is sufficient. Repeat at least twice.
[0169] Acceptance criteria: Nominal molecular weight ± 5% and intrinsic viscosity ± 3% (as shown on the manufacturer's standard certificate).
[0170] calibration
[0171] If the system check passes as expected and the chromatographic preconditions have not changed, no calibration is required.
[0172] If calibration is required:
[0173] Inject 100 μL of polystyrene standard solution at least twice.
[0174] Create a new Multi-Detector Procedure - Homopolymer and perform three calibrations using the data from the first sample.
[0175] Enter all data required for internal calibration of PM, IV, dn / dc, dA / dc and solvent refractive index standard values into the program.
[0176] Calibrate the system according to the equipment specifications and save the new program.
[0177] · Check the suitability of the second injection of the standard solution using the new procedure.
[0178] Measurement steps
[0179] Inject 100 μL of test sample in triplicate.
[0180] The molecular weight of the polymer measured according to the specified technique is 32.5 kDa. The intrinsic viscosity value of the polymer measured according to a similar technique is 0.27 dl / g. It is pointed out that the intrinsic viscosity value is consistent with the viscosity value obtained using this technique, especially with respect to the temperature and elution conditions adopted. Any change in the measurement conditions means that different values will be obtained, since the obtained values directly depend on the measurement conditions.
[0181] Method B:
[0182] equipment
[0183] Automatic Capillary Viscometer
[0184] Automatic polymer viscometer -RPV-2
[0185] Reagents
[0186] HPLC grade chloroform
[0187] ·acetone
[0188] Sample preparation
[0189] 0.5 mg / mL filtered test sample: 2 samples for each polymer to be tested
[0190] condition
[0191] The test was carried out at a temperature of 30.0±0.1°C.
[0192] Measurement steps
[0193] Measure the solvent first, then the sample. Chloroform filtrate (solvent) or sample: Using a glass syringe, filter the solvent or sample through a 0.45 pm PTFE filter, discarding the first few ml.
[0194] Inject 12 to 15 mL of solvent or sample. Be careful not to overfill the viscometer tube. The solvent or sample should be between the scale lines shown. It is important to point out that the intrinsic viscosity value is consistent with the viscosity value obtained using this technique, especially with respect to the temperature, concentration and solvent conditions used. Any change in the measurement conditions means that different values will be obtained, since the values obtained are directly dependent on the measurement conditions.
[0195] Example 2: Use 503 Preparation of reservoir preparations (without irradiation)
[0196] In this example, the following formulations were prepared:
[0197]
[0198] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0199] Example 3: Use 504 Preparation of depot preparations at 16 kGy irradiation dose
[0200] This example illustrates how to control the molecular weight of the polymer to obtain a sterile formulation with a desired in vivo release profile.
[0201] Injecting solid polymers into syringes is a tricky task during the production of injectable formulations. Polymers produced as non-sterile products need to be sterilized before they can be made into formulations that can be injected into the human body. The best way to solve this technical problem may be to sterilize the polymers by gamma or beta irradiation. Irradiation is a challenging issue when using biodegradable polymers because it breaks down the polymer chains into smaller parts. Control of the polymer molecular weight is once again a key parameter in controlling the final characteristics of the product after the sterilization procedure.
[0202] However, the final molecular weight of a polymer used as a feedstock can be predicted by mathematical modeling or by controlling the chain size reduction caused by irradiation because the molecular weight of the polymer is higher than the desired molecular weight. Therefore, once the fill weight of the polymer to be filled into the container (such as the fill weight of the polymer in a syringe) and the bioburden present in the polymer feedstock are determined, the irradiation dose required to obtain a sterile polymer (as specified in ISO 11137) can be selected based on the desired fill weight.
[0203] Next, the initial molecular weight of a given polymer, which is used as a starting material to obtain a polymer having the final molecular weight required for the preparation of a formulation after the irradiation step, can be determined by means of a mathematical model describing the molecular weight loss of the given polymer as a function of the irradiation dose.
[0204] Since the supply of polymers with a specific molecular weight may be limited, a polymer with a molecular weight higher than the molecular weight required according to the determined irradiation dose can be selected, and then the irradiation dose is adjusted to a higher value to obtain a sterile polymer with the desired molecular weight. In this example, a polylactic acid-polyglycolic acid copolymer was sterilized by 16kGy beta ray irradiation under controlled temperature and humidity conditions, wherein the two organic acid monomers each accounted for 50% and the molecular weight was 38kDa. The molecular weight of the resulting polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 31kDa.
[0205]
[0206] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0207] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.27 dl / g.
[0208] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0209] Example 4: Use 504 Preparation of depot preparations at 25 kGy irradiation dose
[0210] This is another example of how to control the molecular weight of the polymer to obtain a sterile formulation with desired in vivo release characteristics.
[0211] The polylactic acid-polyglycolic acid copolymer, in which the two organic acid monomers each accounted for 50% and the molecular weight was 50 kDa, was sterilized by 25 kGy beta ray irradiation under controlled temperature and humidity conditions. The molecular weight of the obtained polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 35 kDa.
[0212]
[0213] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0214] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.28 dl / g.
[0215] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0216] Example 5: Using Lakeshore Preparation of depot preparations with 5050DLG 5E at 25 kGy irradiation dose
[0217] This is another example of how to control the molecular weight of the polymer to obtain a sterile formulation with desired in vivo release characteristics.
[0218] The polylactic acid-polyglycolic acid copolymer, in which the two organic acid monomers each accounted for 50% and the molecular weight was 56 kDa, was sterilized by 25 kGy beta ray irradiation under controlled temperature and humidity conditions. The molecular weight of the obtained polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 45 kDa.
[0219]
[0220] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0221] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.28 dl / g.
[0222] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0223] Example 6: Use 504 Preparation of depot preparations at 25 kGy irradiation dose
[0224] In this example, a polylactic acid-polyglycolic acid copolymer containing 50% organic acid monomers and a molecular weight of 38 kDa was sterilized by 25 kGy beta ray irradiation under controlled temperature and humidity conditions. The molecular weight of the resulting polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 28 kDa.
[0225]
[0226] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0227] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.25 dl / g.
[0228] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0229] Example 7: Use 503 Preparation of depot preparations at 15 kGy irradiation dose
[0230] In this example, a polylactic acid-polyglycolic acid copolymer, wherein the two organic acid monomers each account for 50% and the molecular weight is 32 kDa, was sterilized by 15 kGy beta ray irradiation under controlled temperature and humidity conditions. The molecular weight of the resulting polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 28.3 kDa.
[0231]
[0232] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0233] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.25 dl / g.
[0234] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0235] Example 8: Use 504 Preparation of reservoir preparations (without irradiation)
[0236]
[0237] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=27.49 μm, d(0.5)=79.90 μm, d(0.9)=176.66 μm.
[0238] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.33 dl / g.
[0239] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0240] Example 9: Use 504 Preparation of depot preparations at 25 kGy irradiation dose
[0241] This example demonstrates that this concept is also applicable to achieving an intramuscular formulation of risperidone suitable for injection once every 4 weeks.
[0242] The polylactic acid-polyglycolic acid copolymer, in which the two organic acid monomers each accounted for 50% and the molecular weight was 50 kDa, was sterilized by 25 kGy beta ray irradiation under controlled temperature and humidity conditions. The molecular weight of the obtained polymer was characterized according to the steps described in Example 1. The molecular weight after irradiation was 35 kDa.
[0243]
[0244] The particle size of risperidone was measured by light scattering method, and the particle size distribution was as follows: d(0.1)=17.41 μm, d(0.5)=51.61 μm, d(0.9)=175.32 μm.
[0245] The intrinsic viscosity of the irradiated polymer was calculated according to the technique described in Example 1 to be 0.28 dl / g.
[0246] After the polymer is completely dissolved and a uniform risperidone suspension is formed in the polymer solution, the implantable risperidone preparation can be prepared by connecting the externally threaded and internally threaded syringes and moving the pistons back and forth.
[0247] Example 10: Clinical Evaluation of Sustained Release Injection Composition
[0248] This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial conducted in the United States and Ukraine, in accordance with the "Declaration of Helsinki" and the principles of "Good Clinical Practice" proposed by the International Conference on Harmonization. The trial protocol, amendments, and informed consent forms have been approved by the ethics committees of each trial site, and all subjects have obtained written informed consent before participating in the trial.
[0249] The study consisted of an 8-day screening period immediately prior to the baseline date, followed by a 12-week treatment period and a final 2-week follow-up period. Eligible patients were randomized in a 1:1:1 ratio to receive double-blind intramuscular injections of 75 mg or 100 mg of risperidone (risperidone LAI depot composition) or placebo. After the first dose at the start of the study, each study drug was injected intramuscularly every 4 weeks during the 12-week treatment period.
[0250] Risperidone in the risperidone LAI reservoir composition (Laboratorios Farmacéuticos ROVI, SA, Madrid, Spain) is provided in a kit consisting of two syringes, one of which contains risperidone and polylactic acid-polyglycolic acid copolymer (PLGA) in solid powder form and the other contains dimethyl sulfoxide, a solvent required for reconstitution. The above preparations are all prepared according to Example 11. The matching placebo is also provided in the form of a 2-syringe kit, similar in appearance, but only PLGA is contained in the solid drug syringe. Eligible patients are randomized in a double-blind manner to receive risperidone (risperidone LAI reservoir composition, 75 mg), risperidone (risperidone LAI reservoir composition, 100 mg) or placebo in a ratio of 1:1:1, injected into the buttocks or deltoid muscle once every 4 weeks on the 1st day, the 29th day and the 57th day. After confirming that the patient meets the conditions, a unique random number is immediately assigned through the interactive web response system (IWRS). The dose selected for this study is supported by the results of previous studies and pharmacokinetic models. Patients who had never taken risperidone received a short trial of risperidone 2 mg orally daily for 3 days during the screening period to ensure the absence of allergic reactions before the first dose of study drug.
[0251] Safety was assessed by evaluating adverse events, vital signs, laboratory tests, electrocardiogram, physical examination, ISR (redness, swelling and pressure mark), and scales assessing injection site pain (VAS) and extrapyramidal symptoms (AIMS, BARRAS and SAS), and suicidality (CSSRS).
[0252] Example 11: LAI depot composition (single-dose kit)
[0253] 75 mg dose
[0254] The sustained-release injection composition of 75 mg dose is composed of the following ingredients, the contents of which are shown in the following table.
[0255]
[0256] *Suitable compositions are prepared using PLGA (50:50) with an intrinsic viscosity ranging from about 0.20-0.60 dl / g, about 0.30-0.55 dl / g, about 0.36-0.52 dl / g, about 0.40-0.58 dl / g, or about 0.46-0.51 dl / g.
[0257] 100mg dose
[0258] The sustained-release injection composition for a dose of 100 mg is composed of the following ingredients, the contents of which are shown in the following table.
[0259]
[0260] *Suitable compositions are prepared using PLGA (50:50) with an intrinsic viscosity ranging from about 0.20-0.60 dl / g, about 0.30-0.55 dl / g, about 0.36-0.52 dl / g, about 0.40-0.58 dl / g, or about 0.46-0.51 dl / g.
Claims
1. A sustained-release injection composition comprising about 75 mg of risperidone, DMSO and a PLGA copolymer for treating a risperidone-sensitive disease, disorder or condition in a subject who is concurrently treated with a CYP2D6 (cytochrome P450 2D6) enzyme inhibitor, wherein: The use comprises administering the composition to the subject by intramuscular injection.
2. A sustained-release injection composition comprising about 75 mg of risperidone, DMSO and a PLGA copolymer for treating a risperidone- or paliperidone-sensitive disease, disorder or condition and a CYP2D6 enzyme inhibitor-sensitive disease, disorder or condition in a subject, wherein: The uses include: a) administering to the subject a dose of the sustained-release injection composition comprising about 75 mg of risperidone, DMSO and a PLGA copolymer by intramuscular injection; and b) administering a dose of the CYP2D6 enzyme inhibitor to the subject within 2 to 4 weeks after the administering.
3. A composition for use according to any one of claims 1 or 2, wherein The use comprises injecting at least one dose of the sustained-release injection composition at least about every four weeks, and maintaining the dose of the sustained-release injection composition substantially constant during the treatment period after administration of the CYP2D6 enzyme inhibitor.
4. The composition for use according to claim 3, wherein The CYP2D6 enzyme inhibitor is a selective serotonin reuptake inhibitor (SSRI).
5. The composition for use according to claim 4, wherein The subject is administered the SSRI to treat one or more of the following diseases or disorders: depression, panic attacks, obsessive compulsive disorder (OCD), severe premenstrual syndrome (premenstrual dysphoric disorder), anxiety disorders (social anxiety and / or general anxiety), post-traumatic stress disorder, bulimia nervosa, major depressive disorder, panic disorder, depressive disorder associated with bipolar I disorder, or treatment-resistant depression (depression that has not improved after at least two other treatments).
6. The composition for use according to claim 5, wherein The SSRI is paroxetine or a pharmaceutically acceptable salt thereof or fluoxetine or a pharmaceutically acceptable salt thereof.
7. A sustained-release injection composition comprising about 75 mg of risperidone, for use in a treatment method of converting a subject who is receiving oral risperidone and a CYP2D6 enzyme inhibitor from a once-daily oral risperidone dosage regimen to a risperidone sustained-release injection composition dosage regimen of about once every 28 days, wherein: The treatment method comprises: a) stopping the once-daily oral administration of risperidone to the subject; b) injecting the subject with a sustained-release injection composition according to any one of claims 1 to 6 within 24-48 hours or within 24 hours after the cessation of the administration, wherein the composition comprises a dose of about 75 mg of risperidone, thereby maintaining a therapeutically effective blood concentration of the active molecule in the subject for about 28 days.
8. The sustained-release injection composition for use according to claim 7, wherein: a) when the subject's once-daily oral dose of risperidone is less than 4 mg, no more than 75 mg of risperidone in the sustained-release injection composition is administered to the subject; or b) when the subject's once-daily oral dose of risperidone is 4 mg or more and / or up to 8 mg, no more than 75 mg of risperidone in the sustained-release injection composition is administered to the subject.
9. The sustained-release injection composition for use according to claim 8, wherein: The CYP2D6 dosage is not changed upon initiation of treatment with the sustained-release injection composition.
10. A sustained release injectable composition comprising risperidone, DMSO and a PLGA copolymer for use in treating an SSRI-sensitive disease or disorder and a risperidone- or paliperidone-sensitive disease or disorder in a subject in need thereof, wherein: The use comprises administering to the subject a therapeutically effective dose of 75 mg of risperidone and a therapeutically effective dose of an SSRI in the form of the sustained-release injectable composition.
11. The sustained-release injection composition for use according to claim 10, wherein: a) the SSRI-responsive disease or disorder is selected from the group consisting of depression, panic attacks, obsessive-compulsive disorder (OCD), severe premenstrual syndrome (premenstrual dysphoric disorder), anxiety disorders (social anxiety and / or general anxiety), post-traumatic stress disorder, bulimia nervosa, major depressive disorder, panic disorder, depressive disorder associated with bipolar I disorder, or refractory depression (depression that has not improved after at least two other treatments); b) the risperidone- or paliperidone-sensitive disease or disorder is selected from the group consisting of psychosis, delusional psychosis, dysthymia, obsessive-compulsive disorder, schizophrenia, bipolar disorder, schizoaffective disorder, non-schizophrenic psychosis, Asperger's syndrome, Tourette syndrome, obsessive-compulsive disorder, post-traumatic stress disorder, attention deficit hyperactivity disorder, personality disorder, aggression, depression, dementia, intellectual disability and behavioral disorders, mental retardation and autism, autism spectrum disorder, anxiety disorders, eating disorders, neurasthenic anxiety disorders, insomnia, idiopathic dystonia, substance abuse, and any combination thereof.
12. The sustained-release injection composition for use according to claim 11, wherein: The risperidone-sensitive or paliperidone-sensitive disease or disorder is selected from the group consisting of schizophrenia, schizoaffective disorder, bipolar disorder and bipolar mania.
13. A sustained-release injection composition for use according to any one of the preceding claims, wherein: a) the sustained-release injection composition is administered once every 28 days or approximately monthly by intramuscular injection; b) prior to the administration, greater than 0% and less than 20% of the risperidone by weight is dissolved in the composition; c the ratio of lactic acid to glycolic acid monomers in the PLGA copolymer is between about 50:50 and about 75:25; d) the viscosity of the sustained-release injection composition is in the range of about 0.5-7 Pa.s; e) the weight ratio of DMSO to risperidone in the sustained-release injection composition is between about 5:1 and about 4:1; f) the weight ratio of risperidone to (PLGA+risperidone) in the sustained-release injection composition (expressed as the weight of risperidone as a percentage of the total weight of risperidone plus PLGA) is in the range of about 25-35%.
14. A sustained-release injection composition for use according to any one of the preceding claims, wherein: The use: a) does not include the step of orally administering one or more (plural) risperidone loading doses in the sustained-release injection composition before administering the sustained-release injection composition by intramuscular injection; and / or b) does not include the step of orally administering one or more doses of risperidone during the 28-day or monthly period.
15. A sustained-release injection composition for use according to any one of the preceding claims, wherein: The subject: a) has an unstable mental state and has moderate to severe psychotic symptoms; b) has an acute exacerbation of schizophrenia for the first time; c) is receiving one or more oral antipsychotic drugs; d) has previously experienced one or more acute exacerbations of schizophrenia; e) has worsened mental symptoms or is about to relapse; d) has experienced one or more acute exacerbations of schizophrenia; e is experiencing worsening mental symptoms or is about to relapse; f) is experiencing a recurrence of moderate to severe psychotic symptoms; and / or g) is receiving treatment with a sustained-release injection composition not described in the present invention.
16. A sustained-release injection composition for use according to any one of the preceding claims, wherein: a) the sustained-release injection composition comprises a maintenance dose of about 75 mg of risperidone; b) the sustained-release injection composition comprises risperidone, DMSO and a PLGA copolymer; c) after administration, the sustained-release injection composition forms a biodegradable implant in the muscle; d) before administration, ≤2.5%, ≤5%, ≤7.5%, ≤10%, ≤20% of risperidone is dissolved in the sustained-release injection composition; e) by weight percentage>0%, ≥0.5%, ≥1%, ≥5%, ≥10%, ≥1 5% or up to about 20% of risperidone is dissolved in the composition prior to administration; f) the ratio of lactic acid to glycolic acid monomers in the PLGA copolymer ranges from about 50:50 to about 75:25, from about 35:65 to about 75:25, from about 45:55 to about 70:30, from about 50:50 to about 65:35, or from about 65:35 to about 75:25, from 45:55 to 55:45, or from 48:52 to 52:48, or about 50:50, i.e., 50:50±10% or 75:2 5±10%; g) before administration, the viscosity of the polymer solution used to form the sustained-release injection composition ranges from about 0.5-7 Pa.s, about 0.5-4 Pa.s, about 0.7-4 Pa.s, about 0.5-3.0 Pa.s, about 0.7-3.0 Pa.s, about 1.5-2.1 Pa.s±10%, about 1.5 to about 2.5 Pa.s, about 1.5 to about 2.3 Pa.s or about 1.7-1.8 Pa.s±10%; h) the PLGA copolymer has The invention relates to a composition having an intrinsic viscosity of about 0.20-0.60 dl / g, about 0.30-0.55 dl / g, about 0.36-0.52 dl / g, about 0.40-0.58 dl / g or about 0.46-0.51 dl / g; i) the weight ratio of DMSO to risperidone in the sustained-release injection composition is about 5:1 to about 4:1, about 4.6:1 to about 4.8:1, about 4.6:1 to about 4.7:1, about 4.67:1, about 4.66:1 or about 4.68:1, or about 4.g) the weight ratio of risperidone to (PLGA+risperidone) in the sustained-release injection composition (expressed as the weight of risperidone as a percentage of the total weight of risperidone plus PLGA) is in the range of about 15-40%, about 25-35%, about 30-35%, about 31-35%, about 32-34% or about 33%; k) the PLGA copolymer is terminated with an ester group or a carboxyl group; l) the content of risperidone in the preparation is about 10-15%, about 1 1-14%, about 12-14% or about 13%; m) risperidone is partially dissolved or substantially incompletely dissolved in the composition; n) the PLGA polymer is irradiated with β or γ rays, preferably in the range of 10-30 kGy, more preferably in the range of 15-30 kGy, and most preferably in the range of 16-25 kGy ± 10%; o) the composition is sterile; p) the injectable composition can be continuously administered for at least four weeks from the date of administration. The subject provides a therapeutically effective blood drug concentration; q) before administration, the viscosity of the sustained-release injection composition ranges from about 1.0-7.0 Pa.s, about 1.5-7.0 Pa.s or about 1.8-6.5 Pa.; r) the weight ratio of the solvent (DMSO) to the polymer solution (expressed as the weight of the solvent as a percentage of the total weight of the polymer + solvent) is about 50-75%, about 65-75%, about 60-70%, about 68-72% or about 70%; s) the concentration of the PLGA in the sustained-release injection composition is in the range of 24-50%, 24-40%, 24-30%, 25-27% or 26% (expressed as the weight of the polymer as a percentage of the total weight of the composition); and / or t) based on the total weight of the sustained-release injection composition, the content of DMSO in the injectable reservoir composition is about 55-65%, about 57-63%, about 60-62% or about 61% by weight. .
17. A sustained-release injection composition for use according to any one of the preceding claims, wherein: After the administration, the sustained-release injection composition provides a blood drug concentration curve of the active molecule: a) the blood drug concentration curve shows a maximum value in the first 6 days, the first 3 days, the first 2 days, or the first 1 day or 2 days of the dosing period; b) the blood drug concentration curve shows a maximum value in the last 1 to 24 days of the 4-week dosing period; c) the blood drug concentration curve shows a maximum value in the first few days of the dosing period, and the blood drug concentration shows a maximum value in the remaining days of the dosing period; d) the blood drug concentration curve is basically flat during the dosing period (the standard deviation is within the range of ±30%, ±25%, ±20%, ±15%, ±10% or ±5% of the mean or median); e) the blood drug concentration curve reaches a peak value in the first 48 hours or the first 72 hours or the first 24 to 48 hours of the dosing period; and / or f) the blood drug concentration curve reaches a peak value in the last 10 to 28 days or the last 18 to 25 days of the 4 to 5 week dosing period.
18. The sustained-release injection composition for use according to any one of the preceding claims, further comprising: a) providing a container containing DMSO and a container containing risperidone and the PLGA copolymer, mixing the contents of the containers to form the sustained-release injection composition, and then administering the sustained-release injection composition; or b) providing a container containing DMSO, a container containing risperidone, and a container containing the PLGA copolymer, mixing the contents in the containers to form the injectable depot composition, and then administering the injectable depot composition.
19. The sustained-release injection composition for use according to claim 18, wherein: The container is contained in a kit.
20. The sustained-release injection composition for use according to claim 19, wherein: The kit comprises a single dose of risperidone.
Citation Information
Patent Citations
Sustained delivery formulations of risperidone compounds
US10010612B2
Methods for the preparation of injectable depot compositions
US10058504B2
Sustained release small molecule drug formulation
US10058554B2
Antipsychotic injectable depot composition
US10085936B2
Antipsychotic injectable depot composition
US10182982B2
